Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma

por Li, Shuyu D., Martial, Annia, Schrock, Alexa B., Liu, Jane J.
Publicado 2017

A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers

por Ayers, Kristin L., Ma, Meng, Debussche, Gaspard, Corrigan, David, McCafferty, Jonathan, Lee, Kyeryoung, Newman, Scott, Zhou, Xiang, Hirsch, Fred R., Mack, Philip C., Liu, Jane J., Schadt, Eric E., Chen, Rong, Li, Shuyu D.
Publicado 2021

Analysis of Real‐World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death‐1 and Programmed Cell Death‐Ligand 1 Inhibitors in Advanced Non‐Sma...

por Ayers, Kristin L., Mullaney, Tommy, Zhou, Xiang, Liu, Jane J., Lee, Kyeryoung, Ma, Meng, Jones, Scott, Li, Li, Redfern, Arielle, Jappe, Whitney, Liu, Zongzhi, Goldsweig, Howard, Yadav, Kamlesh K., Hahner, Nicholas, Dietz, Matthew, Zimmerman, Michelle, Prentice, Tony, Newman, Scott, Veluswamy, Rajwanth, Wisnivesky, Juan, Hirsch, Fred R., Oh, William K., Li, Shuyu D., Schadt, Eric E., Chen, Rong
Publicado 2021